However, it remains unclear to what extent correction of hypophosphatemia is able to rescue the mineralization defect because the effect of anti-FGF23 therapy on the local levels of mineralization inhibitors, such as ASARM peptides, osteopontin, and PPi, is not known. The gene discussed is FGF23; the disease is hypophosphatemia.